Tax Inversion Crackdown Seems More Bite Than Brawn
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pfizer/Allergan merger was targeted by legislators and advocacy groups this week, but there doesn't appear to be any substantive change on the horizon that could potentially block the merger.